TabletsClinical Overview
Mycophenolate Mofetil Tablets (500mg) and Mycophenolate Sodium Gastro-Resistant Tablets (360mg) is an oral prodrug of mycophenolic acid (MPA) on the WHO Model List of Essential Medicines. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo guanine nucleotide synthesis. Because T- and B-lymphocytes rely almost exclusively on the de novo pathway for purine generation (unlike other cell types that utilize the salvage pathway), mycophenolate selectively blocks lymphocyte proliferation and antibody production. Indicated in combination with cyclosporine/tacrolimus and corticosteroids for prophylaxis of organ rejection in kidney, heart, and liver allografts, and for induction and maintenance of lupus nephritis.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily (morning and evening), approximately 12 hours apart on an empty stomach (1 hour before or 2 hours after meals) with water. Swallow whole; do NOT crush, chew, or divide. Note: 360 mg of mycophenolate sodium delivers equimolar MPA to 500 mg of mycophenolate mofetil.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, nausea, vomiting, abdominal pain, leukopenia, anemia, thrombocytopenia, infection. Rare/Severe: Severe opportunistic infections (CMV viremia, BK virus nephropathy), Progressive Multifocal Leukoencephalopathy (PML), and pure red cell aplasia (PRCA).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: First-trimester pregnancy loss and congenital malformations (severe embryofetal toxicity); female patients must use two reliable forms of contraception and complete negative pregnancy tests. Black Box Warning: Increased risk of opportunistic infections and lymphomas. Black Box Warning: Pure red cell aplasia. Space antacids and sevelamer at least 2 hours apart.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.